Streetbeat News

MEDP

Medpace Holdings, Inc.

https://www.medpace.com

Industry

Medical - Diagnostics & Research

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Open

308.42

Mkt cap

9.8B

Volume

217K

High

317.64

P/E Ratio

27.72

52-wk high

459.77

Low

305.88

Div yield

N/A

52-wk low

268.80

Mizuho analyst Ann Hynes has initiated coverage on Medpace Holdings (NASDAQ:MEDP) with a Buy rating and set a price target of $435.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 9:22 am

Medpace Holdings (NASDAQ:MEDP) has significantly outperformed the market, with an annualized return of 48.03% over the past 5 years, growing a $100 investment to $720.49. The company's market capitalization stands at $12.06 billion.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 3:30 pm

Medpace Holdings (NYSE:MEDP) has seen an increase in short interest, now at 4.77% of its float, with 984 thousand shares sold short. This represents a 3.92% rise since the last report, requiring approximately 5.65 days for traders to cover their short positions. The increase in short interest can indicate a bearish market sentiment towards MEDP, although it has less short interest compared to its peer group average of 5.12%. This data suggests investors are showing more interest in shorting the stock, but it does not necessarily predict a price drop.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 5:15 pm

Over the past 5 years, Medpace Holdings (NASDAQ:MEDP) has significantly outperformed the market, with an annualized return of 47.25%, turning a $100 investment into $676.82. The company now has a market capitalization of $12.28 billion.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 2:00 pm

Guggenheim analyst Sandy Draper maintains a Buy rating on Medpace Holdings (MEDP) and raises the price target from $453 to $464.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 5:43 pm

Baird analyst Eric Coldwell has maintained an Outperform rating on Medpace Holdings (MEDP) and increased the price target from $446 to $454.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:50 am

In Tuesday's after-market session, several healthcare stocks showed notable movements. Gainers included 180 Life Sciences, ABVC BioPharma, Medpace Holdings, Adverum Biotechnologies, Black Diamond Therapeutic, and Verve Therapeutics, with increases ranging from 4.94% to 7.4%. On the losing side, Fresh2 Group, Kiora Pharmaceuticals, Alterity Therapeutics, Tiziana Life Sciences, Calidi Biotherapeutics, and Nuwellis saw declines between 7.06% and 12.9%. Medpace Holdings' stock rise followed their Q1 earnings release.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 8:31 pm

Medpace Holdings (NASDAQ:MEDP) has been evaluated by 5 analysts over the last three months, showing a diverse range of opinions from bullish to bearish. The average 12-month price target for MEDP has been raised to $437.00, indicating a 26.12% increase from the previous target. Analysts from firms like Jefferies, Deutsche Bank, UBS, and Baird have updated their ratings and price targets, reflecting positive sentiment towards the company's performance and market position. Medpace, a contract research organization, has shown strong financials with significant revenue growth, high net margin, and solid returns on equity and assets, alongside prudent debt management.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 4:01 pm

Medpace Holdings' shares surged following the company's announcement of robust FY24 guidance. Additionally, Jefferies upgraded MEDP to Buy and increased its price target to $450.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 3:12 pm

Jefferies analyst David Windley upgraded Medpace Holdings (MEDP) from Hold to Buy and increased the price target from $340 to $450, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 3:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.